These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 21750204

  • 1. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.
    Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, Goubar A, Dorvault N, Lazar V, Job B, Besse B, Validire P, Girard P, Lacroix L, Hasmats J, Dufour F, André F, Soria JC.
    Clin Cancer Res; 2011 Sep 01; 17(17):5562-72. PubMed ID: 21750204
    [Abstract] [Full Text] [Related]

  • 2. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 01; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 3. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
    Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH.
    Lung Cancer; 2008 Jun 01; 60(3):401-7. PubMed ID: 18036700
    [Abstract] [Full Text] [Related]

  • 4. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.
    Zhonghua Zhong Liu Za Zhi; 2009 Jan 01; 31(1):33-7. PubMed ID: 19538866
    [Abstract] [Full Text] [Related]

  • 5. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May 01; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 6. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M, Choi YD, Cho HJ, Ban HJ, Oh IJ, Kim KS, Song SY, Na KJ, Ahn SJ, Choi S, Kim YC.
    Respirology; 2012 Jan 01; 17(1):127-33. PubMed ID: 21899657
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N.
    J Thorac Oncol; 2007 Oct 01; 2(10):902-6. PubMed ID: 17909351
    [Abstract] [Full Text] [Related]

  • 11. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 01; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 12. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E, Rosell R.
    Expert Rev Mol Diagn; 2007 May 01; 7(3):261-8. PubMed ID: 17489733
    [Abstract] [Full Text] [Related]

  • 13. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer.
    Okuda K, Sasaki H, Hikosaka Y, Kawano O, Yukiue H, Yano M, Fujii Y.
    J Surg Res; 2011 Jun 15; 168(2):206-12. PubMed ID: 20070981
    [Abstract] [Full Text] [Related]

  • 14. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
    Das M, Riess JW, Frankel P, Schwartz E, Bennis R, Hsieh HB, Liu X, Ly JC, Zhou L, Nieva JJ, Wakelee HA, Bruce RH.
    Lung Cancer; 2012 Aug 15; 77(2):421-6. PubMed ID: 22555222
    [Abstract] [Full Text] [Related]

  • 15. [EGFR gene copy number, ERCC1 and BRCA1 protein expression and their relationship in non-small cell lung cancer].
    Deng QH, Qiu Y, Mo MC, Zhang X, Xiong XG, Jiang M, He P, Wen DP, Zheng GX, He JX.
    Zhonghua Zhong Liu Za Zhi; 2011 Jul 15; 33(7):508-12. PubMed ID: 22093627
    [Abstract] [Full Text] [Related]

  • 16. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA, Mountzios G, Soria JC.
    Curr Opin Pulm Med; 2007 Jul 15; 13(4):284-9. PubMed ID: 17534174
    [Abstract] [Full Text] [Related]

  • 17. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
    Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW.
    Lung Cancer; 2010 Aug 15; 69(2):155-64. PubMed ID: 19962780
    [Abstract] [Full Text] [Related]

  • 18. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
    Sereno M, Cejas P, Moreno V, Belda-Iniesta C, López R, Nistal M, Feliu J, De Castro Carpeño J.
    Int J Oncol; 2012 Jun 15; 40(6):2104-10. PubMed ID: 22344449
    [Abstract] [Full Text] [Related]

  • 19. [Expression of ERCC1 mRNA and its impact on the prognosis of patients with non-small cell lung cancer].
    Ma W, Li W, Gao M, Li XN.
    Zhonghua Zhong Liu Za Zhi; 2011 May 15; 33(5):371-4. PubMed ID: 21875468
    [Abstract] [Full Text] [Related]

  • 20. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer.
    Simon GR, Sharma S, Cantor A, Smith P, Bepler G.
    Chest; 2005 Mar 15; 127(3):978-83. PubMed ID: 15764785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.